Therefore, EZH2 inhibitors can enhance tumor cell immunogenicity by reshaping the epigenetic landscape of cancer cells and favoring the expression of genes associated with both the presentation of new antigens and the recruitment of anti-tumor immune cells. Here, EZH2 is linked to cancer.